SAN DIEGO, April 15, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results fiscal year ended December 31, 2013, and other recent developments.
Focus on Gene Therapy and Regenerative Medicine Biologics
The Company recently announced that the U.S.-based Cardium Therapeutics operations will be primarily focused on the clinical and commercial development of its Generx® and Excellagen® advanced regenerative medicine therapeutics.
Help employers find you! Check out all the jobs and post your resume.
